Last reviewed · How we verify

Aroxybutynin and Atomoxetine — Competitive Intelligence Brief

Aroxybutynin and Atomoxetine (Aroxybutynin and Atomoxetine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic/Norepinephrine reuptake inhibitor combination. Area: Urology/Neurology.

phase 3 Anticholinergic/Norepinephrine reuptake inhibitor combination M3 muscarinic acetylcholine receptor; norepinephrine transporter (NET) Urology/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Aroxybutynin and Atomoxetine (Aroxybutynin and Atomoxetine) — Apnimed. This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aroxybutynin and Atomoxetine TARGET Aroxybutynin and Atomoxetine Apnimed phase 3 Anticholinergic/Norepinephrine reuptake inhibitor combination M3 muscarinic acetylcholine receptor; norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic/Norepinephrine reuptake inhibitor combination class)

  1. Apnimed · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aroxybutynin and Atomoxetine — Competitive Intelligence Brief. https://druglandscape.com/ci/aroxybutynin-and-atomoxetine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: